NCT03291002: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC |
|
|
| Active, not recruiting | 1 | 98 | Europe, RoW | CV8102, CV8102 + anti-PD-1 therapy | CureVac AG, Syneos Health, Cromos Pharma LLC | Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic | 10/22 | 02/23 | | |